Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 12/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 7/20 | 0.41 |
| ▸ | CA12 | O43570 | 6/20 | 0.41 |
| ▸ | CA9 | Q16790 | 6/20 | 0.41 |
| ▸ | CA4 | P22748 | 2/20 | 0.41 |
| ▸ | CA6 | P23280 | 2/20 | 0.41 |
| ▸ | CA5A | P35218 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SCNN1A | P37088 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10693466 | 0.94 | CA2 (0.49) | CA2LMNATSHRALDH1A1NT5E | |
| SCHEMBL10966406 | 0.92 | CA2 (0.50) | CA2LMNATSHRALDH1A1NT5E | |
| SCHEMBL10695940 | 0.92 | CA2 (0.50) | CA2LMNATSHRALDH1A1NT5E | |
| SCHEMBL10693380 | 0.92 | CA2 (0.50) | CA2LMNATSHRALDH1A1NT5E | |
| SCHEMBL10693881 | 0.92 | CA2 (0.50) | CA2LMNATSHRALDH1A1NT5E | |
| SCHEMBL10688804 | 0.92 | CA2 (0.50) | CA2LMNATSHRALDH1A1NT5E | |
| SCHEMBL3244085 | 0.92 | CA2 (0.50) | CA2LMNATSHRALDH1A1NT5E | |
| SCHEMBL10694619 | 0.92 | CA2 (0.50) | CA2LMNATSHRALDH1A1NT5E | |
| SCHEMBL10693169 | 0.92 | CA2 (0.50) | CA2LMNATSHRALDH1A1NT5E | |
| SCHEMBL17212140 | 0.88 | LMNA (0.48) | CA2LMNATSHRALDH1A1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358932-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-06-14 | — | — | US | disclosed |
| CN-105849102-B | N- (1-hydroxy-3 (pyrrolidinyl) propan-2-yl) pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | 生物马林药物股份有限公司 | 2020-10-16 | — | — | CN | disclosed |
| US-20190276398-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARM INC (US) | 2019-09-12 | — | — | US | disclosed |
| US-10239832-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-03-26 | — | — | US | disclosed |
| EP-3063141-B1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARM INC (US) | 2018-02-28 | — | — | EP | disclosed |
| EP-2964221-B1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-2964220-B1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME (US) | 2017-10-04 | — | — | EP | disclosed |
| US-9688654-B2 | Compounds inhibiting leucine-rich repeat kinase enzyme activity | MERCK SHARP & DOHME CORP. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20160280643-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2016-09-29 | — | — | US | disclosed |
| US-9440952-B2 | Compounds inhibiting leucine-rich repeat kinase enzyme activity | MERCK SHARP & DOHME CORP. (US) | 2016-09-13 | — | — | US | disclosed |
| US-4973691-A | ANALGESICS | Spojene Podniky Prozdravotnickou Vyrobu (SPOFA) (CS) | 1990-11-27 | — | — | US | disclosed |
| US-4820715-A | TREATING NAUSEA AND GASTRIC DISORDERS | BRISTOL-MYERS COMPANY (US) | 1989-04-11 | — | — | US | disclosed |
| US-4808624-A | ANTIEMETICS | BRISTOL-MYERS COMPANY (US) | 1989-02-28 | — | — | US | disclosed |
| US-4792551-A | 9-anthryloxyaminoalkanes and related compounds as anti-inflammatory and analgetic agents | SYNTEX (U.S.A.) INC. (US) | 1988-12-20 | — | — | US | disclosed |
| US-4736056-A | Process for the production of malonic acid derivative compounds | UNION CARBIDE AGRICULTURAL PRODUCTS COMPANY, INC., T.W. ALEXANDER DR., RESEARCH TRIANGLE PARK, NC. A CORP. OF PA. | 1988-04-05 | — | — | US | disclosed |
| US-4593029-A | Enzyme inhibitor | SYNTEX (U.S.A.) INC. (US) | 1986-06-03 | — | — | US | disclosed |
| EP-0132351-A2 | 9-Anthryloxyaminoalkanes and related compounds, processes for their preparation and pharmaceutical compositions containing them | SYNTEX (U.S.A.) INC. (US) | 1985-01-30 | — | — | EP | disclosed |
| US-4419354-A | IMMUNOLOGY, ANTITUMOR AGENTS | AMERICAN CYANAMID COMPANY (US) | 1983-12-06 | — | — | US | disclosed |
| US-4125538-A | ANALGESIC, ANTITUSSIVE | BRISTOL-MYERS COMPANY (US) | 1978-11-14 | — | — | US | disclosed |
| US-4064260-A | Anti-inflammatory diarylimidazothiazoles and their corresponding S-oxides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11358932-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | GBA1, UGCG, GBA2 | CA2 1390/4885LMNA 1291/4885TSHR 3456/4885 |
| US-20190276398-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, UGCG, GBA2 | CA2 1390/4885LMNA 1291/4885TSHR 3456/4885 |
| US-20160280643-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, UGCG, GBA2 | CA2 1516/4885LMNA 1286/4885TSHR 3328/4885 |
| US-10239832-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | GBA1, UGCG, GBA2 | CA2 1516/4885LMNA 1286/4885TSHR 3328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.